Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Manic and bipolar mood disorders and disturbances

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Manic and bipolar mood disorders and disturbances. Displaying page 1 of 1.
    EudraCT Number: 2017-000803-25 Sponsor Protocol Number: RGH-MD-25 Start Date*: 2019-10-02
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION...
    Medical condition: Bipolar I disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10026753 Manic and bipolar mood disorders and disturbances HLGT
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2021-006861-39 Sponsor Protocol Number: GH001-BD-202 Start Date*: 2022-06-20
    Sponsor Name:GH Research Ireland Limited
    Full Title: A Phase 2 Clinical Trial of GH001 in Patients with Bipolar II Disorder and a Current Major Depressive Episode (GH001-BD-202)
    Medical condition: Bipolar II Disorder
    Disease: Version SOC Term Classification Code Term Level
    26.1 10037175 - Psychiatric disorders 10026753 Manic and bipolar mood disorders and disturbances HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023992-24 Sponsor Protocol Number: MEMAP1 Start Date*: 2011-08-26
    Sponsor Name:University of Leipzig
    Full Title: International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate
    Medical condition: acute mania and hypomania (ICD-10: F30.0, F30.1, F31.0, F31.1)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004873 10000852 Acute mania LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012003-26 Sponsor Protocol Number: RIS-NAP-4022 Start Date*: 2010-04-13
    Sponsor Name:Janssen-Cilag International, NV
    Full Title: Evaluation of Growth, Sexual Maturation, and Prolactin-Related Adverse Events in the Pediatric Population Exposed to Atypical Antipsychotic Drugs
    Medical condition: Long-term safety data in children and adolescents will be collected from a population of patients with a diagnosis of schizophrenia, bipolar mania, autistic disorder or conduct and other disruptive...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10039626 Schizophrenia LLT
    12.1 10026753 Manic and bipolar mood disorders and disturbances HLGT
    12.1 10003805 Autism LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Prematurely Ended) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-005734-20 Sponsor Protocol Number: R076477-SCA-3002 Start Date*: 2008-04-24
    Sponsor Name:Janssen L.P.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Flexible Dose Paliperidone ER in the Treatment of Subjects with Schizoaffective Disorder
    Medical condition: Schizoaffective disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039621 Schizoaffective disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:38:34 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA